Article
Oncology
S. Sugawara, J-S Lee, J-H Kang, H. R. Kim, N. Inui, T. Hida, K. H. Lee, T. Yoshida, H. Tanaka, C-T Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C-J Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
Summary: This international study evaluated nivolumab with bevacizumab and chemotherapy as a first-line treatment for nonsquamous NSCLC, showing significantly longer progression-free survival and higher objective response rates in the nivolumab group compared to the placebo group in the interim analysis. The incidence of severe treatment-related adverse events was comparable between the two groups.
ANNALS OF ONCOLOGY
(2021)
Article
Medicine, General & Internal
Yin Tao, Xue-Ting Tang, Xing Li, An-Shan Wu, Hou-Shen Zhou, Cheng-fang Zhou
Summary: This study evaluated the role of neoadjuvant chemotherapy (NACT) with intraperitoneal perfusion of bevacizumab in advanced ovarian cancer. The results showed that treatment with the TCB regimen significantly reduced serum levels of CA125 and ascites volume, as well as intraoperative blood loss and operation time. Patients treated with the TCB regimen had a higher surgical satisfaction rate, and a lower incidence of postoperative complications compared with the TC group. No severe complications were observed between the two groups during chemotherapy.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Yoshimasa Shiraishi, Junji Kishimoto, Takayuki Shimose, Yukihiro Toi, Shunichi Sugawara, Isamu Okamoto
Summary: The study aims to evaluate the efficacy and safety of combination therapy with carboplatin, nanoparticle albumin-bound paclitaxel, and atezolizumab in patients with impaired renal function and advanced nonsquamous non-small cell lung cancer. If the study demonstrates positive results, this combination regimen may become a treatment option for this patient population.
Article
Oncology
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frederic Selle, Simona Frezzini, Ugo De Giorgi, Patricia Pautier, Alessandra Bologna, Michele Orditura, Coraline Dubot, Angiolo Gadducci, Serafina Mammoliti, Isabelle Ray-Coquard, Elena Zafarana, Enrico Breda, Laure Favier, Antonio Ardizzoia, Saverio Cinieri, Remy Largillier, Daniela Sambataro, Emmanuel Guardiola, Rossella Lauria, Carmela Pisano, Francesco Raspagliesi, Giovanni Scambia, Gennaro Daniele, Francesco Perrone
Summary: This study focused on the efficacy of continuing bevacizumab combined with chemotherapy in ovarian cancer patients after first-line treatment. The results showed a significant prolongation of progression-free survival in the bevacizumab group, with more adverse events observed in the bevacizumab combination therapy group, although the mortality rate was slightly higher than that in the standard chemotherapy group.
Article
Oncology
G. E. Konecny, A. E. Wahner Hendrickson, T. M. Davidson, B. J. Winterhoff, S. Ma, S. Mahner, J. Sehouli, P. A. Fasching, G. Feisel-Schwickardi, M. Poelcher, L. D. Roman, A. Rody, B. Y. Karlan, S. A. Mullany, H. Chen, I. L. Ray-Coquard, D. M. Provencher, A. Yachnin, P. H. Cottu, J. A. Glaspy, P. Haluska, D. J. Slamon
Summary: This study investigated the efficacy and safety of adding ganitumab to CP chemotherapy in primary EOC patients, but did not show improvement in PFS. The results do not support further study of ganitumab in unselected EOC patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles A. Secord, David G. Mutch, Alessandro Santin, David P. Warshal, Nick M. Spirtos, Paul A. DiSilvestro, Olga B. Ioffe, David S. Miller
Summary: This phase III randomized trial compared the efficacy of paclitaxel and carboplatin (PC) with paclitaxel and ifosfamide (PI) in the treatment of uterine carcinosarcoma. The results showed that PC was not inferior to PI and should be considered as the standard treatment for uterine carcinosarcoma.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Hye Ryun Kim, Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng-Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong-Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa
Summary: ONO-4538-52/TASUKI-52 study evaluated the efficacy and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for advanced nsNSCLC. Updated data showed that nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer overall survival (OS) compared to the placebo combination, indicating its potential as a standard first-line treatment for advanced nsNSCLC.
Article
Oncology
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, Manolo D'Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crino, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito
Summary: This study investigated the efficacy of adding bevacizumab to erlotinib as a treatment for EGFR-mutated NSCLC. The results showed that the combination therapy prolonged progression-free survival, but also increased toxicity.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, YongQian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, XiaoRong Dong, Faguang Jin, Hongjun Gao, Guangyu An, Cuimin Ding, Xiaodong Jiang, Jianping Xiong, Xiangdong Zhou, Sheng Hu, Ping Lu, Anwen Liu, Shuliang Guo, Jianjin Huang, Chengchu Zhu, Jian Zhao, Beili Gao, Yinglan Chen, Chengping Hu, Jian Zhang, Hongmei Zhang, Hui Zhao, Yanfei Tai, Xinjing Ma, Wei Shi, CameL Study Grp
Summary: The addition of camrelizumab to first-line chemotherapy significantly improves the progression-free survival of patients with advanced nonsquamous NSCLC. It provides long-term survival benefit with manageable toxicity and durable response. These results support the combination of camrelizumab and chemotherapy as a first-line treatment for advanced nonsquamous NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Satoshi Watanabe, Kazuko Sakai, Naoya Matsumoto, Jun Koshio, Akira Ishida, Tetsuya Abe, Daisuke Ishikawa, Tomohiro Tanaka, Ami Aoki, Tomosue Kajiwara, Kenichi Koyama, Satoru Miura, Yuka Goto, Tomoki Sekiya, Ryo Suzuki, Kohei Kushiro, Toshiya Fujisaki, Naohiro Yanagimura, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Yu Saida, Hirohisa Yoshizawa, Kazuto Nishio, Toshiaki Kikuchi
Summary: Patients with ALK-positive lung cancer after failure of ALK-tyrosine kinase have limited treatment options. This study demonstrates that the combination of alectinib and bevacizumab shows clinical efficacy with acceptable toxicity in these patients.
Article
Oncology
Satoshi Oizumi, Kei Takamura, Toshiyuki Harada, Motoko Tachihara, Naoto Morikawa, Ryoichi Honda, Satoshi Watanabe, Tetsuhiko Asao, Mamoru Kunisaki, Tatsuro Fukuhara, Rintaro Noro, Eiki Kikuchi, Yasuhiro Tsutani, Toshiyuki Tenma, Kunihiko Kobayashi, Hirotoshi Dosaka-Akita
Summary: This study examined the efficacy and safety of systemic chemotherapy for patients with pulmonary sarcomatoid carcinomas (PSCs). The results indicate that carboplatin/paclitaxel with bevacizumab may be an effective first-line treatment for PSCs. However, further research is needed to verify the role of cytotoxic chemotherapy in this rare and aggressive tumor.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Immunology
Hayato Kawachi, Kei Kunimasa, Yoji Kukita, Harumi Nakamura, Keiichiro Honma, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Hanako Kuhara, Kazumi Nishino, Yu Mizote, Takashi Akazawa, Hideaki Tahara, Toru Kumagai
Summary: SMARCA4-deficient thoracic sarcoma is a progressive thoracic malignancy, and first-line ABCP treatment demonstrates durable efficacy in SMARCA4-DTS regardless of the degree of PD-L1 expression.
Article
Oncology
Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel Clarke-Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca Baergen
Summary: This study compared the efficacy and toxicity of cisplatin plus paclitaxel with carboplatin plus paclitaxel in patients with resected advanced ovarian cancer. The results showed that the carboplatin plus paclitaxel regimen had less toxicity, was easier to administer, and was not inferior to the cisplatin plus paclitaxel regimen.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Terumi Tanigawa, Nobuhiro Takeshima, Hideki Ishikawa, Shin Nishio, Tomoka Usami, Takaharu Yamawaki, Tetsuro Oishi, Kei Ihira, Hisamori Kato, Mayako Goto, Motoaki Saito, Yusuke Taira, Masatoshi Yokoyama, Tadahiro Shoji, Eiji Kondo, Atsushi Mori, Takeshi Yokoi, Naomi Iwasa-Inoue, Yasuyuki Hirashima, Takayuki Nagasawa, Motoki Takenaka, Mikio Mikami, Toru Sugiyama, Takayuki Enomoto
Summary: Paclitaxel-carboplatin and bevacizumab therapy is an effective and safe treatment for metastatic, recurrent, and persistent uterine cervical cancer. Maintenance therapy can improve progression-free survival.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Aidong Qu, Shiying Zhang, Hongxia Zou, Sixiu Li, Dandan Chen, Yaowen Zhang, Songsong Li, Huijun Zhang, Ji Yang, Yunkai Yang, Yubao Huang, Xiuling Li, Yuntao Zhang
Summary: This study found that bevacizumab combined with chemotherapy significantly prolonged the progression-free survival (PFS) and overall survival (OS) of advanced non-squamous non-small-cell lung cancer (nsqNSCLC) patients with EGFR mutation.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
